Author

HA Azim

Observed names: Azim HA, H A Azim, H.A. Azim, HA Azim Jr, Ha Azim, Hamdy A Azim, Jr HA Azim

Observed institutions: University of Southern California, Roche (Switzerland), Universidad Complutense de Madrid, Oslo University Hospital, Université Libre de Bruxelles, Sunnybrook Health Science Centre, Royal Marsden NHS Foundation Trust, Harvard University, Cairo University, University of Southern Denmark, University of Milan, University of Ioannina, Universidad Peruana Cayetano Heredia, Chinese Academy of Medical Sciences & Peking Union Medical College, Washington University in St. Louis, Leiden University Medical Center, Universitair Ziekenhuis Leuven, Peter MacCallum Cancer Centre, Institut Jules Bordet, Institut Gustave Roussy, Erasmus Hospital, Institute of Oncology Ljubljana, Breast International Group, IPO Porto, Dana-Farber Cancer Institute, Royal Marsden Hospital, Vall d'Hebron Hospital Universitari, German Breast Group, Servier (France), Sana Klinikum Offenbach, International Breast Cancer Study Group, Helios Hospital Berlin-Buch, Cairo University hospitals, Instituto de Investigación Sanitaria Gregorio Marañón, European Institute of Oncology, Institut Curie, American University of Beirut, KU Leuven

OpenAlex ID: A5109625337

Understanding the biology of triple-negative breast cancer

2012 · C. Criscitiello, H.A. Azim, et al. · Annals of Oncology · 162

PDF

ecancermedicalscience

2016 · Ha Azim, O Gentilini, et al. · ecancermedicalscience · 58

PDF

Abstract OT2-01-08: POSITIVE: A study evaluating pregnancy and disease outcome and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13)

2016 · O Pagani, A Partridge, et al. · Cancer Research · 9

1814O Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial

2024 · H.A. Azim, S. Niman, et al. · Annals of Oncology · 6

PDF

Abstract OT1-01-06: POSITIVE: A study evaluating Pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with endocrine responsIVE breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13)

2019 · O Pagani, AH Partridge, et al. · Cancer Research · 6

Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial

2016 · HA Azim, A Sonnenblick, et al. · Cancer Research · 6

Abstract OT3-02-01: POSITIVE: A study evaluating pregnancy and disease outcome and safety of interrupting endocrine therapy for young women with endocrine-responsive breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13)

2017 · O Pagani, AH Partridge, et al. · Cancer Research · 5

Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplIfied oestrogeN rEceptor poSitive metaStatic breast cancEr

2016 · F Andre, F Daly, et al. · Cancer Research · 5

The Discrepancy Between High Pathological Complete Response (PCR) Rate and Low Breast Conserving Surgery (BCS) Following Neoadjuvant Therapy: Analysis from the Neoaltto Trial (BIG 1-06)

2012 · C. Criscitiello, H.A. Azim, et al. · Annals of Oncology · 5

PDF

504 Safety of pregnancy in breast cancer survivors: a meta-analysis

2010 · H.A. Azim, L. Santoro, et al. · European Journal of Cancer Supplements · 4

Abstract S4-4: Independent validation of Genomic Grade in the BIG 1-98 study

2012 · C Sotiriou, M Ignatiadis, et al. · Cancer Research · 3

415O Predictive factors of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in the POSITIVE trial

2025 · I. Demeestere, S.M. Niman, et al. · ESMO Open · 2

PDF

Review article optimizing the use of her-2/neu targeting agents in breast cancer : a developing nation perspective.

2007 · Hamdy A Azim, Hatem A Azim · PubMed · 2

Abstract P6-04-13: The role of precision medicine in "real-life" management of breast cancer patients: A survey assessing the current use and attitudes towards tumor molecular sequencing in clinical practice

2016 · I Gingras, A Sonnenblick, et al. · Cancer Research · 1

Abstract P6-07-22: Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer (BC): a pooled in-silico analysis

2012 · Jr HA Azim, S Singhal, et al. · Cancer Research · 1

Abstract P6-07-14: Mutational and transcriptomic characterization of breast cancer (BC) arising in young patients (pts) and during pregnancy and their associations with long-term outcome

2012 · Jr HA Azim, FA Peccatori, et al. · Cancer Research · 1

144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy

2023 · H.A. Azim, B.E. Pöllinger · ESMO Open

PDF

Abstract PD5-06: The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer

2019 · B Nguyen, M Marion, et al. · Cancer Research

Abstract P6-18-16: Ribociclib (RIBO) + letrozole (LET) in older patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Preliminary subgroup results from the phase 3b CompLEEment-1 trial

2019 · A Ring, S Borstnar, et al. · Cancer Research

Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

2018 · Azim HA, Omar A, et al. · Dove Medical Press (Taylor and Francis Group)

PDF

Abstract P2-05-01: Whole genome sequencing reveals enrichment of mutations in mucin gene family in breast cancer diagnosed during pregnancy

2018 · B Nguyen, D Venet, et al. · Cancer Research

Abstract P1-05-17: Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling

2017 · B Nguyen, DN Brown, et al. · Cancer Research

Abstract CS1-2: Small Tumor – Aggressive Biology: When They Collide!

2012 · MJ Piccart, HA Azim · Cancer Research

P4-11-03: Prognosis of Pregnancy-Associated Breast Cancer: A Meta-Analysis Involving 39,415 Patients.

2011 · HA Azim, L Santoro, et al. · Cancer Research

P1-12-01: Pregnancy during and Following Adjuvant Trastuzumab in Patients with HER2−Positive Breast Cancer: An Analysis from the HERA Trial (BIG 01-01).

2011 · HA Azim, O Metzger-Filho, et al. · Cancer Research

Works count: 26

Citation count: 276

H-index: 6

I10-index: 2